Connor, Clark & Lunn Investment Management Ltd. Ventyx Biosciences, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 945,206 shares of VTYX stock, worth $2.66 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
945,206
Previous 871,605
8.44%
Holding current value
$2.66 Million
Previous $1 Million
101.8%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding VTYX
# of Institutions
125Shares Held
44.8MCall Options Held
35.2KPut Options Held
40.6K-
Black Rock Inc. New York, NY4.77MShares$13.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.23MShares$11.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.51MShares$9.87 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$8.71 Million0.23% of portfolio
-
Sio Capital Management, LLC New York, NY2.58MShares$7.26 Million1.12% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $159M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...